arrow
B

Bastien Job

gustave roussy
H指数:22
被引数:3,765

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

达波妥昔单抗德鲁克替康在晚期非小细胞肺癌中的疗效、安全性及生物标志物分析:ICARUS-LUNG01 II期研究

2026-04-170
OAAI
Glial-to-mesenchymal transition of tumor Schwann cells drives the genetic burden in MPNSTs from neurofibromatosis type 1 mouse model

肿瘤雪旺细胞的神经胶质-间质转化驱动1型神经纤维瘤病小鼠模型mpnst的遗传负担

2025-11-120
PRE
Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial

帕梯他马单抗德鲁克替康在HRHER2+−晚期乳腺癌中的治疗:一项II期临床试验

2025-09-040
OAAI
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer

用于晚期胰腺癌功能精准医学的类器官

2024-10-012
OA
Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)
2024-05-020
PRE
TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signaling
2024-03-281
OA
Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer

在晚期结直肠癌患者的功能精准医学中实施患者衍生的类器官

2023-10-2510
OAAI
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
2023-07-24130
OAAI
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1+Antiangiogenesis in Malignant Pleural Mesothelioma
2023-01-208
OAAI
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis
2022-03-1516
OA
EFFICACY, SAFETY AND ANCILLARY ANALYSES OF PEMBROLIZUMAB IN COMBINATION WITH NINTEDANIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED ADVANCED MESOTHELIOMA
2021-11-100
OA
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia
2019-12-0237
OAAI
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
2017-06-01529
OAAI